Abstract
Proteomics offers unique insights into human biology and drug development, but few studies have directly compared the utility of different proteomics platforms. We measured 2,168 plasma proteins in 3,976 Chinese adults using both OLINK and SomaScan platforms and compared their genetic determinants and associations with traits and disease risk. For 1,694 proteins with one-to-one matched reagents, there was a modest between platform correlation (median rho=0.20). OLINK-proteins had fewer trans-pQTLs (766 vs 812 proteins) but more cis-pQTLs (725 vs 565) than SomaScan-proteins, including 342 with colocalising cis-pQTLs. Moreover, 1,095 OLINK- and 963 SomaScan-proteins showed significant associations with BMI, while 279 and 165 proteins were significantly associated with IHD, respectively. Addition of these IHD-associated proteins to conventional risk factors yielded NRIs for IHD of 15.3% and 17.1% for OLINK and SomaScan respectively. The results demonstrate the complementarity of different proteomic platforms and should inform assay selection in future population and clinical studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The CKB baseline survey and the first re-survey were supported by the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up and subsequent resurveys have been supported by Wellcome grants to Oxford University (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and grants from the National Natural Science Foundation of China (82192901, 82192904, 82192900) and from the National Key Research and Development Program of China (2016YFC0900500).The UK Medical Research Council (MC_UU_00017/1, MC_UU_12026/2, MC_U137686851), Cancer Research UK (C16077/A29186, C500/A16896) and British Heart Foundation (CH/1996001/9454), provide core funding to the Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford University for the project. The proteomic assays were supported by BHF (FS/18/23/33512), Novo Nordisk, OLINK, SomaScan and NDPH. DNA extraction and genotyping were supported by GlaxoSmithKline and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). Computation used the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Ethical Review Committee of the Chinese Centre for Disease Control and Prevention (Beijing, China, 005/2004) and the Oxford Tropical Research Ethics Committee, University of Oxford (UK, 025-04), and all participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
- Abbreviations
- ALDH2
- Aldehyde Dehydrogenase 2 Family Member
- ANML
- Adaptive normalization by maximum likelihood
- BMI
- Body mass index
- CKB
- China Kadoorie Biobank
- CVD
- Cardiovascular disease
- DBP
- Diastolic blood pressure
- FDR
- False discovery rate
- GDF15
- Growth Differentiation Factor 15
- GHR
- Growth Hormone Receptor
- GO
- Gene Ontology
- GWAS
- Genome-wide association study
- HDL
- High-density lipoprotein
- IHD
- Ischaemic heart disease
- LD
- Linkage disequilibrium
- LOD
- Limit of detection
- MAC
- Minor allele count
- MAF
- Minor allele frequency
- MHC
- Major histocompatibility complex
- NRI
- Net Reclassification Index
- NPX
- Normalized Protein eXpression
- NRI
- Net reclassification index
- PLA2G7
- Phospholipase A2 Group VII
- pQTL
- Protein quantitative trait loci
- QC
- Quality control
- RFU
- Relative fluorescence units
- ROC
- Receiver operating characteristic
- SBP
- Systolic blood pressure
- SOMAmer
- Slow offrate modified aptamers
- TNC
- Tenascin C
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.